Healthcare solutions provider Solventum (NYSE:SOLV) reported Q3 CY2025 results topping the market’s revenue expectations , but sales were flat year on year at $2.10 billion. Its non-GAAP profit of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

In other recent news, Solventum has announced a significant $1 billion share repurchase program alongside the acquisition of Acera Surgical for up to $850 million. The acquisition is expected to ...

President and Chief Executive Officer — Bryan C. Hanson Chief Financial Officer — Wayde D. McMillan Head of Investor Relations — Amy Wakeham Management stated the company is actively evaluating ...

*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum. (a) 2025 restructuring costs primarily related to the Company's Transform for the Future ...

2024年4月、工業用素材・事務用品大手「3M」から分離上場したグローバルヘルスケア企業。 材料科学やデータサイエンスなどを活用した広範な製品ポートフォリオを開発、製造、商品化している。主力の「メドサーグ（医療ソリューション）」事業では ...

Solventum beat estimated earnings by 4.67%, reporting an EPS of $1.57 versus an estimate of $1.5. Revenue was down $76.00 million from the same period last year. The company beat on EPS by $0.07 in ...

In the latest quarter, 5 analysts provided ratings for Solventum (NYSE:SOLV), showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light ...

Solventum, Minnesota’s newest Fortune 500 company, is finding its footing after starting its first full year of operations on shakier ground. The 3M spinoff commenced 2025 with a deflated stock, which ...

PAUL, Minn. - Solventum (NYSE:SOLV) announced Thursday it has entered into a definitive agreement to acquire Acera Surgical, a privately held bioscience company specializing in regenerative wound care ...